iScience-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-04-22 一命二运三风水来自北京

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：原代培养;脑肿瘤
经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2022-12-16 ms7000000921958379 来自北京

偏重的研究方向：审稿速度
经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬

64 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2023-04-20 123a6632m26暂无昵称

大家有遇到过小修后外审很长时间的情况嘛

127 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-04-20 ms2000001471285364 来自湖北省

想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-03-26 易挥发来自广东省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：外泌体;肿瘤标志物
经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。

12 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-03-09 ms3000000526945160 来自湖北省

偏重的研究方向：分子生物学
经验分享：想问下with editor 10多天了正常吗

12 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-04-06 ms6000000307870975 来自北京

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：生态学
经验分享：2023年8月投稿
2023年11月第一轮给了大修
2024年2月28日修回
2024年3月20日pre-accept
2024年3月26日格式修改修回
2024年4月1日 with editor。。。

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-03-12 ms2000000185262432 来自广西

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing

21 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2023-06-30 山蛙来自湖北省

谁能告诉我这还是当初好多人说的潜力股吗？

43 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199825, encodeId=779a21998254c, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：原代培养;脑肿瘤 经验分享：投cell report后让转投iScience，2024.1.2转投，2024.1.4 under review，2024.1.29审稿意见返回让大修，给了2个月时间，2024.3.18修回，2024.3.26原则性接受，让修改格式，2024.4.3修回，4.9让再次修改格式，4.9马上修回，4.18正式接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=一命二运三风水, createdTime=Mon Apr 22 19:21:02 CST 2024, time=2024-04-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106386, encodeId=df33210638637, content=偏重的研究方向：审稿速度 经验分享：iscience小修，返回去，二审一个月还是under review，要毕业啊，太煎熬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22606160927, createdName=ms7000000921958379, createdTime=Fri Dec 16 20:55:32 CST 2022, time=2022-12-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2127250, encodeId=ed2d212e250b3, content=大家有遇到过小修后外审很长时间的情况嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu Apr 20 14:28:42 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199466, encodeId=d4822199466d5, content=想问一下这个杂志现在对wb原始数据有什么要求吗？重复三次或者是全膜？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4039126481, createdName=ms2000001471285364, createdTime=Sat Apr 20 17:03:06 CST 2024, time=2024-04-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2195435, encodeId=c5cb2195435a8, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：外泌体;肿瘤标志物 经验分享：速度有点慢，去年8月从cell report medicine转投过来的，一周内就送审，但是一直在找reviewer，今年2月份才回来3个reviewer的意见，两个好评，一个让上传原始组学数据，两周后修回，然后就是原则性接收，后面改格式又用了两周。总之就是比较慢，急需毕业的慎投。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f8a1685210, createdName=易挥发, createdTime=Tue Mar 26 14:15:49 CST 2024, time=2024-03-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192230, encodeId=da892192230d2, content=偏重的研究方向：分子生物学 经验分享：想问下with editor 10多天了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 14:18:13 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2192708, encodeId=626d2192e08b7, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：从ebiomedicine转投过来，第二天就under review了，但一直没邀请到审稿人，一个多月了，着急ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:03:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145697, encodeId=68fa214569e2f, content=谁能告诉我这还是当初好多人说的潜力股吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Fri Jun 30 21:26:40 CST 2023, time=2023-06-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2194672, encodeId=309521946e220, content=偏重的研究方向：癌症生物学 经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47d98750326, createdName=ms9000001758785175, createdTime=Fri Mar 22 14:10:20 CST 2024, time=2024-03-22, status=1, ipAttribution=上海)]

2024-03-22 ms9000001758785175 来自上海

偏重的研究方向：癌症生物学
经验分享：请问投稿后只有自动回复的邮件，没有编辑邮箱，想催稿联系谁呢，网上没看到编辑部邮箱

7 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务